Professor David E. Olson is a chemical neuroscientist with expertise spanning central nervous system medicinal chemistry, molecular/cellular neurobiology, and behavioral neuropharmacology. He studied chemistry and biology at Union College before receiving his Ph.D. in chemistry from Stanford University. After his graduate work, he completed postdoctoral training in neuroscience at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. Professor Olson joined the faculty at the University of California, Davis in 2015, where he established a research program at the interface of chemistry and neuroscience. His research focuses on understanding how small molecules influence neural plasticity, learning, memory, and mood. In 2019, he co-founded Delix Therapeutics—a company developing non-hallucinogenic analogs of psychedelics for treating a variety of brain disorders. He is an associate editor at ACS Chemical Neuroscience and has received numerous awards including the Jordi Folch-Pi Award from the American Society for Neurochemistry, the Sigma Xi Young Investigator Award, and the Life Young Investigator Award, among many others.